Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

The number of patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) has increased constantly over the last years due to advances in transplant technology development, supportive care, transplant safety, and donor availability. Currently, acute myeloid leukemia (AML) is the most frequent indication for alloHCT. However, disease relapse remains the main cause of therapy failure. Therefore, concepts of maintaining and, if necessary, reinforcing a strong graft-versus-leukemia (GvL) effect is crucial for the prognosis and long-term survival of the patients. Over the last decades, it has become evident that effective immunosurveillance after alloHCT is an entangled complex of donor-specific characteristics, leukemia-associated geno-and phenotypes, and acquired resistance mechanisms. Furthermore, adoption of effector cells such as natural killer (NK) cells, alloreactive and regulatory T-cells with their accompanying receptor repertoire, and cell-cell interactions driven by messenger molecules within the stem cell and the bone marrow niche have important impact. In this review of pre-and posttransplant elements and mechanisms of immunosurveillance, we highlight the most important mechanisms after alloHCT.

Automated summary

The number of patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) has been increasing due to advances in transplant technology, supportive care, transplant safety, and donor availability. Acute myeloid leukemia (AML) is the most common indication for alloHCT, but disease relapse remains a major challenge. Maintaining a strong graft-versus-leukemia (GvL) effect is crucial for patient prognosis and long-term survival.